• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

BCR-ABL1 转基因斑马鱼模型的开发重现慢性髓性白血病(CML)样疾病,并为 CML 机制提供新的见解。

Development of BCR-ABL1 Transgenic Zebrafish Model Reproducing Chronic Myeloid Leukemia (CML) Like-Disease and Providing a New Insight into CML Mechanisms.

机构信息

Unit of Biotechnology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.

Unit of Hematology, Department of Clinical and Experimental Sciences, University of Brescia, Bone Marrow Transplant Unit, ASST Spedali Civili, 25123 Brescia, Italy.

出版信息

Cells. 2021 Feb 19;10(2):445. doi: 10.3390/cells10020445.

DOI:10.3390/cells10020445
PMID:33669758
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7922348/
Abstract

Zebrafish has proven to be a versatile and reliable experimental in vivo tool to study human hematopoiesis and model hematological malignancies. Transgenic technologies enable the generation of specific leukemia types by the expression of human oncogenes under specific promoters. Using this technology, a variety of myeloid and lymphoid malignancies zebrafish models have been described. Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasia characterized by the fusion gene, derived from the t (9;22) translocation causing the Philadelphia Chromosome (Ph). The BCR-ABL1 protein is a constitutively activated tyrosine kinas inducing the leukemogenesis and resulting in an accumulation of immature leukemic cells into bone marrow and peripheral blood. To model Ph+ CML, a transgenic zebrafish line expressing the human was generated by the Gal4/UAS system, and then crossed with the hsp70-Gal4 transgenic line. The new line named (pUAS:CFP/hsp70-Gal4), presented altered expression of hematopoietic markers during embryonic development compared to controls and transgenic larvae showed proliferating hematopoietic cells in the caudal hematopoietic tissue (CHT). The present transgenic zebrafish would be a robust CML model and a high-throughput drug screening tool.

摘要

斑马鱼已被证明是一种多功能且可靠的体内实验工具,可用于研究人类造血以及模拟血液系统恶性肿瘤。转基因技术可通过在特定启动子下表达人类癌基因来产生特定类型的白血病。利用这项技术,已经描述了多种骨髓性和淋巴性恶性肿瘤的斑马鱼模型。慢性髓细胞白血病(CML)是一种克隆性髓系增殖性肿瘤,其特征在于融合基因,源自导致费城染色体(Ph)的 t(9;22)易位。BCR-ABL1 蛋白是一种组成性激活的酪氨酸激酶,可诱导白血病发生,并导致不成熟的白血病细胞在骨髓和外周血中积聚。为了模拟 Ph+CML,通过 Gal4/UAS 系统生成了表达人 的转基因斑马鱼系,然后与 hsp70-Gal4 转基因系杂交。新的系命名为(pUAS:CFP/hsp70-Gal4),与对照和转基因幼虫相比,在胚胎发育过程中造血标记物的表达发生改变,并且转基因幼虫的尾造血组织(CHT)中存在增殖性造血细胞。这种新型的转基因斑马鱼将成为一种强大的 CML 模型和高通量药物筛选工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5d4/7922348/c521234a0df1/cells-10-00445-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5d4/7922348/eb7cf07150b6/cells-10-00445-g001a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5d4/7922348/cde40fcc4495/cells-10-00445-g002a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5d4/7922348/4352b7fb2835/cells-10-00445-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5d4/7922348/47de71a9cbc8/cells-10-00445-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5d4/7922348/7fd449997c8f/cells-10-00445-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5d4/7922348/3ddd23934ebf/cells-10-00445-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5d4/7922348/5ec40923eb71/cells-10-00445-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5d4/7922348/c521234a0df1/cells-10-00445-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5d4/7922348/eb7cf07150b6/cells-10-00445-g001a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5d4/7922348/cde40fcc4495/cells-10-00445-g002a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5d4/7922348/4352b7fb2835/cells-10-00445-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5d4/7922348/47de71a9cbc8/cells-10-00445-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5d4/7922348/7fd449997c8f/cells-10-00445-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5d4/7922348/3ddd23934ebf/cells-10-00445-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5d4/7922348/5ec40923eb71/cells-10-00445-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5d4/7922348/c521234a0df1/cells-10-00445-g008.jpg

相似文献

1
Development of BCR-ABL1 Transgenic Zebrafish Model Reproducing Chronic Myeloid Leukemia (CML) Like-Disease and Providing a New Insight into CML Mechanisms.BCR-ABL1 转基因斑马鱼模型的开发重现慢性髓性白血病(CML)样疾病,并为 CML 机制提供新的见解。
Cells. 2021 Feb 19;10(2):445. doi: 10.3390/cells10020445.
2
Human BCR/ABL1 induces chronic myeloid leukemia-like disease in zebrafish.人 BCR/ABL1 可诱导斑马鱼罹患慢性髓性白血病样疾病。
Haematologica. 2020 Mar;105(3):674-686. doi: 10.3324/haematol.2019.215939. Epub 2019 Jul 9.
3
c-myb is involved in CML progression and is a therapeutic target in the zebrafish CML model.c-myb 参与 CML 的进展,是斑马鱼 CML 模型中的一个治疗靶点。
Animal Model Exp Med. 2024 Apr;7(2):136-144. doi: 10.1002/ame2.12282. Epub 2022 Oct 27.
4
Chronic myelogenous leukemia: molecular and cellular aspects.慢性粒细胞白血病:分子与细胞层面
J Cancer Res Clin Oncol. 1998;124(12):643-60. doi: 10.1007/s004320050228.
5
miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.miR-96 通过靶向慢性髓系白血病原始细胞转化中的 BCR-ABL1 癌基因发挥肿瘤抑制作用。
Biomed Pharmacother. 2019 Nov;119:109413. doi: 10.1016/j.biopha.2019.109413. Epub 2019 Sep 10.
6
Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.在接受P210 bcr/abl转导骨髓的小鼠中高效快速诱导慢性粒细胞白血病样骨髓增殖性疾病
Blood. 1998 Nov 15;92(10):3780-92.
7
Chronic Myeloid Leukemia (CML) Mouse Model in Translational Research.转化研究中的慢性髓性白血病(CML)小鼠模型
Methods Mol Biol. 2016;1438:225-43. doi: 10.1007/978-1-4939-3661-8_13.
8
An overview of chronic myeloid leukemia and its animal models.慢性髓性白血病及其动物模型概述。
Sci China Life Sci. 2015 Dec;58(12):1202-8. doi: 10.1007/s11427-015-4965-6. Epub 2015 Nov 18.
9
Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.慢性髓性白血病中导致伊马替尼耐药的BCR-ABL1激酶结构域突变的检测
Methods Mol Biol. 2013;999:25-39. doi: 10.1007/978-1-62703-357-2_2.
10
Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder.干扰素共有序列结合蛋白(ICSBP)的表达在Bcr-Abl诱导的小鼠慢性粒细胞白血病样疾病中下调,并且ICSBP的强制共表达可抑制Bcr-Abl诱导的骨髓增殖性疾病。
Mol Cell Biol. 2000 Feb;20(4):1149-61. doi: 10.1128/MCB.20.4.1149-1161.2000.

引用本文的文献

1
Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent.慢性髓性白血病的不同体外模型表现出不同特征:生物复制品并非生物学等效。
Cell Biol Int. 2025 May;49(5):570-586. doi: 10.1002/cbin.70007. Epub 2025 Mar 1.
2
Zebrafish: a convenient tool for myelopoiesis research.斑马鱼:一种用于骨髓生成研究的便捷工具。
Cell Regen. 2023 Jan 3;12(1):2. doi: 10.1186/s13619-022-00139-2.
3
Current Views on the Interplay between Tyrosine Kinases and Phosphatases in Chronic Myeloid Leukemia.

本文引用的文献

1
Molecular Testing in CML between Old and New Methods: Are We at a Turning Point?慢性粒细胞白血病新旧方法中的分子检测:我们正处在转折点吗?
J Clin Med. 2020 Nov 27;9(12):3865. doi: 10.3390/jcm9123865.
2
RT-qPCR versus Digital PCR: How Do They Impact Differently on Clinical Management of Chronic Myeloid Leukemia Patients?逆转录定量聚合酶链反应(RT-qPCR)与数字聚合酶链反应(Digital PCR):它们对慢性髓性白血病患者的临床管理有何不同影响?
Case Rep Oncol. 2020 Oct 15;13(3):1263-1269. doi: 10.1159/000510440. eCollection 2020 Sep-Dec.
3
Clinical Features and Outcomes of Patients With Chronic Myeloid Leukemia Presenting With Isolated Thrombocytosis: A Systematic Review and a Case From Our Institution.
慢性髓性白血病中酪氨酸激酶与磷酸酶相互作用的当前观点
Cancers (Basel). 2021 May 12;13(10):2311. doi: 10.3390/cancers13102311.
以孤立性血小板增多症为表现的慢性髓性白血病患者的临床特征及预后:一项系统评价及来自我们机构的1例病例报告
Cureus. 2020 Jun 23;12(6):e8788. doi: 10.7759/cureus.8788.
4
Chronic Myeloid Leukemia Prognosis and Therapy: Criticisms and Perspectives.慢性髓系白血病的预后与治疗:批判与展望
J Clin Med. 2020 Jun 2;9(6):1709. doi: 10.3390/jcm9061709.
5
Response and Resistance to BCR-ABL1-Targeted Therapies.BCR-ABL1 靶向治疗的反应和耐药性。
Cancer Cell. 2020 Apr 13;37(4):530-542. doi: 10.1016/j.ccell.2020.03.006.
6
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.欧洲白血病网络 2020 年治疗慢性髓性白血病的建议。
Leukemia. 2020 Apr;34(4):966-984. doi: 10.1038/s41375-020-0776-2. Epub 2020 Mar 3.
7
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP.管理无治疗缓解的慢性髓性白血病:来自 GIMEMA CML WP 的建议。
Blood Adv. 2019 Dec 23;3(24):4280-4290. doi: 10.1182/bloodadvances.2019000865.
8
How I investigate chronic myelomonocytic leukemia.我如何研究慢性髓单核细胞白血病。
Int J Lab Hematol. 2020 Apr;42(2):101-108. doi: 10.1111/ijlh.13145. Epub 2019 Dec 16.
9
Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update.慢性髓性白血病疾病进展和酪氨酸激酶抑制剂治疗耐药的机制:最新进展。
Int J Mol Sci. 2019 Dec 5;20(24):6141. doi: 10.3390/ijms20246141.
10
Tackling Acute Lymphoblastic Leukemia-One Fish at a Time.分而治之,攻克急性淋巴细胞白血病。
Int J Mol Sci. 2019 Oct 25;20(21):5313. doi: 10.3390/ijms20215313.